MalkanUYGunesGEtgulSAslanTBalabanSHaznedarogluIC. Management of de novo CML and imatinib-induced acute rhabdomyolysis with the second-generation TKI, dasatinib. Ann Pharmacother. 2015;49:740-742. doi:10.1177/1060028015579425.
2.
UzBDolasikI. An unexpected and devastating adverse event of dasatinib: rhabdomyolysis. Leuk Res Rep. 2015;5:1-2. doi:10.1016/j.lrr.2015.11.001.
3.
AlJohaniNICaretteSLiptonJH. Inclusion body myositis in a patient with chronic myeloid leukemia treated with dasatinib: a case report. J Med Case Rep. 2015;9:214. doi:10.1186/s13256-015-0674-9.
4.
KantarjianHMShahNPCortesJE. Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION). Blood. 2012;119:1123-1129. doi:10.1182/blood-2011-08-376087.
5.
VerstovsekSGolemovicMKantarjianH. AMN 107, a novel aminopyrimidine inhibitor of p190 Bcr-Abl activation and of in vitro proliferation of Philadelphia-positive acute lymphoblastic leukemia cells. Cancer. 2005;104:1230-1236.
6.
HochausARostiGCrossNC. Frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the European ENEST1st study [published online October6, 2015]. Leukemia. doi:10.1038/leu.2015.270.
7.
BermanENicolaidesMMakiRG. Altered bone and mineral metabolism in patients receiving imatinib mesylate. N Engl J Med. 2006;354:2006-2013.
